Eliem Therapeutics, Inc.
ELYM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14 | $15 | $26 | $23 |
| G&A Expenses | $16 | $10 | $19 | $12 |
| SG&A Expenses | $16 | $10 | $19 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $52 | $0 | $0 | $0 |
| Operating Expenses | $82 | $37 | $45 | $36 |
| Operating Income | -$82 | -$21 | -$45 | -$36 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $8 | -$14 | -$0 | -$12 |
| Pre-Tax Income | -$74 | -$35 | -$45 | -$47 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$74 | -$35 | -$45 | -$47 |
| % Margin | – | – | – | – |
| EPS | -1.53 | -1.3 | -1.72 | -1.81 |
| % Growth | -17.7% | 24.4% | 5% | – |
| EPS Diluted | -1.53 | -1.3 | -1.72 | -1.81 |
| Weighted Avg Shares Out | 67 | 27 | 26 | 26 |
| Weighted Avg Shares Out Dil | 67 | 27 | 26 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $2 | $0 |
| Depreciation & Amortization | $0 | $21 | $45 | $36 |
| EBITDA | -$82 | -$14 | $1 | -$36 |
| % Margin | – | – | – | – |